MOTS-C vs 5-Amino-1MQ
MOTS-c is a 16-amino-acid microprotein encoded within the mitochondrial 12S rRNA gene, described in the literature as a retrograde signalling molecule acting on AMPK, folate-methionine one-carbon metabolism and nuclear stress-response gene expression. 5-Amino-1MQ is a synthetic small molecule that inhibits nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and so consumes S-adenosylmethionine and diverts nicotinamide away from NAD+ salvage. The pairing is popular in vendor material because both are framed as ways of raising cellular energy metabolism, and because a superficial reading places both near NAD+ biology. The published record does not connect them. Searches of PubMed and of Europe PMC full text returned no publication that names both, so there is no head-to-head experiment, no shared review and no combined assay. Both evidence bases are also preclinical for the intervention itself, which means the comparison below is between two sets of rodent and cell-culture findings, not between two clinically tested options.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has administered or tested MOTS-c and 5-Amino-1MQ together, and no located publication names both. PubMed searches pairing MOTS-c and its expansion, mitochondrial open reading frame of the 12S rRNA type-c, with 5-amino-1MQ, 5-amino-1-methylquinolinium, 5A1MQ and nicotinamide N-methyltransferase inhibitor returned no records, and the same combinations against Europe PMC full text returned none either. The handful of open-access papers that mention MOTS-c and nicotinamide N-methyltransferase in the same document concern the enzyme in cancer and post-translational modification biology, do not involve 5-Amino-1MQ, and are not comparative work. Both compounds are frequently described as converging on NAD+ and AMPK, but that convergence is a reading of two separate literatures rather than a result anyone has measured: no experiment has placed the mitochondrial peptide and the enzyme inhibitor in the same model, so their relative effects, and any interaction between them, are unreported.
Side by side.
| MOTS-C | 5-Amino-1MQ | |
|---|---|---|
| Evidence maturity | Preclinical only | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 12 | 8 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A 16-residue peptide encoded in the mitochondrial genome within the 12S rRNA gene, so it is endogenous and its expression changes with exercise and age. Its coding region carries an East-Asian-specific polymorphism, m.1382A>C, producing a K14Q substitution. | A synthetic small molecule, 5-amino-1-methylquinolinium, containing no amino acids and having no endogenous counterpart. It was designed as a selective, membrane-permeable inhibitor of a specific enzyme rather than derived from any human sequence. |
| Mechanism as described in the literature | Retrograde mitochondrial-to-nuclear signalling. The original report described targeting of the folate-methionine one-carbon cycle and activation of AMPK; later work reported direct binding and activation of casein kinase 2 in skeletal muscle, and mouse experiments indicated the mitochondrial bioenergetic effects depended on intact PGC-1alpha and AMPK signalling. | Enzyme inhibition. Blocking nicotinamide N-methyltransferase reduces production of 1-methylnicotinamide, preserves S-adenosylmethionine and increases NAD+ availability in adipose tissue and muscle. Enzymology work published in 2025 reported that some inhibitors of this class are themselves substrates whose methylated metabolites are more potent than the parent compound. |
| Size of the evidence base | Fifteen verified studies in this library, spanning 2015 to 2026, and unusually diverse in design: rodent intervention work, a systematic review and meta-analysis, a large mitochondrial genotype meta-analysis and several human observational cohorts. | Fifteen verified studies in this library, spanning 2014 to 2026, and homogeneous in design: rodent metabolic and muscle experiments, in vitro enzymology and medicinal chemistry, plus narrative reviews of the target. |
| Best-characterised finding | Prevention of diet-induced and age-dependent insulin resistance in mice, reported in the 2015 paper that identified the peptide, together with improved physical performance in young, middle-aged and old mice after administration in a 2021 report that also documented exercise-induced increases in endogenous expression in humans. | Reduction of body weight and adiposity in diet-induced obese mice without reduced food intake, reported for the quinolinium inhibitor class in 2018 and reproduced for 5-amino-1MQ specifically in 2024, where glucose tolerance and liver histopathology also improved. |
| Human data | Present but observational. No controlled trial has administered exogenous MOTS-c to humans. What exists is biomarker work measuring circulating endogenous levels in acute coronary syndrome, obesity, polycystic ovary syndrome, cerebral palsy and heart failure, plus a genotype association study across three East Asian cohorts totalling 27,527 participants. | None of any kind. No human clinical trial has been published, and human pharmacokinetics, oral bioavailability and safety are uncharacterised. No study has confirmed target engagement in people using 1-methylnicotinamide or any other biomarker. |
| Consistency of the human signal | Inconsistent. Circulating MOTS-c moves in opposite directions across conditions, being reported lower in diabetes and polycystic ovary syndrome but higher in obesity and acute coronary syndrome, and in one cohort it did not change after surgical weight loss. Assay standardisation also differs between studies, so its interpretation as a marker is not settled. | Not applicable, since no human measurements of the compound or of its target engagement have been published. The only human-relevant data are expression studies of the enzyme itself in adipose tissue and tumour biology. |
| Safety signals reported | No controlled human administration has occurred, so a human safety profile does not exist. The rodent literature does not report a characteristic adverse signal, but long-term safety, immunogenicity and pharmacokinetics in people are unestablished. | No human safety data exist. The open questions raised in the preclinical literature concern sustained inhibition of a methylation enzyme: the consequences for methylation potential, polyamine metabolism and tumour biology over time have not been resolved. |
| Regulatory and anti-doping status | No approved medicine anywhere. MOTS-c was added as a new example to the metabolic modulators class of the World Anti-Doping Agency's 2025 Prohibited List, and a mass-spectrometric plasma detection method for doping control purposes was published in 2019. | No approved medicine anywhere, and no nicotinamide N-methyltransferase inhibitor has reached approval for any indication. The compound was not located in the anti-doping analytical literature, and no prohibited-list entry or validated detection method was identified for it. |
And what it does not.
Neither compound has been tested against the other, and neither has been tested in a controlled human trial, so the published record cannot say which is more effective at anything. What it can say is that the two files fail in different places. MOTS-c has the broader spread of designs, including rodent administration studies, a systematic review of circulating levels and a large genotype meta-analysis, but its human data are entirely observational, the direction of the biomarker signal reverses between conditions, and no one has given the peptide to a person under controlled conditions. 5-Amino-1MQ has the tighter and more mechanistically explicit story, with a defined enzyme target, independent pharmacological confirmation across several inhibitor chemotypes and reproducible rodent obesity and aged-muscle results, but it has no human data at all and unresolved questions about long-term methylation-pathway inhibition. The claim that they work through complementary arms of the same NAD+ and AMPK network is a plausible reading of two separate literatures, not a measured result.
Common questions.
- Has any experiment combined MOTS-c and 5-Amino-1MQ?
No. Searches of PubMed and of Europe PMC full text, using the peptide's full expansion as well as its abbreviation and covering the inhibitor's chemical name, its abbreviations and the generic term for its enzyme target, returned no publication naming both. The combination is described only in vendor and blog material. Because no shared experiment exists, nothing has been reported about whether the two produce additive, redundant or opposing effects in any model.
- Do both compounds raise NAD+?
Only one of them has that as its described mechanism. Inhibiting nicotinamide N-methyltransferase reduces the diversion of nicotinamide into 1-methylnicotinamide and so preserves substrate for NAD+ salvage, which the rodent literature links to increased adipose NAD+. The MOTS-c literature describes AMPK activation, one-carbon metabolism and casein kinase 2 binding rather than direct NAD+ elevation, and mouse experiments indicated its mitochondrial effects depended on PGC-1alpha and AMPK signalling rather than on a change in NAD+ availability.
- Which compound has been measured in people?
MOTS-c has, but as an endogenous molecule rather than as a treatment. Human studies have measured circulating levels in acute coronary syndrome, obesity, polycystic ovary syndrome, cerebral palsy and diabetic heart failure, and a genotype study examined a mitochondrial variant in its coding region across large East Asian cohorts. None of these administered the peptide. 5-Amino-1MQ has not been measured in any published human study, and no clinical trial of it has been reported.
- Is the fact that MOTS-c is endogenous an advantage over a synthetic inhibitor?
The published record does not treat it as one. Being endogenous establishes that a molecule has a physiological role, which the observational biomarker studies support, but it says nothing about what happens when the molecule is administered from outside, at concentrations and in patterns the body does not produce. That question requires controlled trials, and for MOTS-c none exist. The distinction is descriptive rather than a demonstrated advantage in either direction.
- Why is one of these prohibited in sport and the other not listed?
MOTS-c was added as an example to the metabolic modulators class of the World Anti-Doping Agency's 2025 Prohibited List, and a plasma detection method for doping control was published in 2019, reflecting concern about performance effects reported in rodent exercise studies. No prohibited-list entry or validated detection method for 5-Amino-1MQ was located in the anti-doping literature. Absence from that literature reflects analytical and regulatory attention rather than any finding about the compound's safety.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.